Alkermes plc
ALKS
株式のランク
#2726
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
株価
$41.39
最終同期: 2026-10-16
時価総額
$6.94B
変化（1日）
3.22%
変化（1年）
36.78%
国
IE
取引 Alkermes plc (ALKS)
カテゴリー
Healthcare
Alkermes plc（ALKS）の営業利益率
October 2026 時点の営業利益率 TTM: 7.03%
Alkermes plc の最新の財務報告と株価によると、現在の営業利益率（TTM）は 7.03% です。2023 年末時点では 24.90% でした。
Alkermes plc の営業利益率の履歴（2000 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | 7.03% | -73.96% |
| 2024 | 27.00% | 8.43% |
| 2023 | 24.90% | -4,627.27% |
| 2022 | -0.55% | -106.60% |
| 2021 | 8.33% | -176.99% |
| 2020 | -10.82% | -27.82% |
| 2019 | -14.99% | 65.45% |
| 2018 | -9.06% | -44.65% |
| 2017 | -16.37% | -41.49% |
| 2016 | -27.98% | -21.62% |
| 2015 | -35.70% | 153.55% |
| 2014 | -14.08% | -199.09% |
| 2013 | 14.21% | 0.00% |
| 2012 | 14.21% | -162.77% |
| 2011 | -22.64% | -7.40% |
| 2010 | -24.45% | 1.28% |
| 2009 | -24.14% | -158.46% |
| 2008 | 41.29% | -3,659.48% |
| 2007 | -1.16% | -125.22% |
| 2006 | 4.60% | -43.90% |
| 2005 | 8.20% | -108.51% |
| 2004 | -96.39% | -61.15% |
| 2003 | -248.12% | 42.63% |
| 2002 | -173.96% | 50.88% |
| 2001 | -115.30% | 116.00% |
| 2000 | -53.38% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 38.59% | -94.51% |
US
|
|
| -149.01% | -121.20% |
US
|
|
| 25.57% | -96.36% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -95.90% |
NL
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。